Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1)] . everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. therapeutic drug monitoring (tdm) of everolimus and cyclosporine is recommended for all patients receiving these products [see dosage and administration (2.2, 2.3)]. everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus is to be administered no earlier than 30 days post transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5), clinical studies (14.2)] . tdm of everolimus and tacrolimus is recommended for all patients receiving these products [see dosage and administration (2.3, 2.5)] . the safety and efficacy of everolimus has not been established in the following populations: - kidney transplant patients at high immunologic risk - recipients of transplanted organs other than kidney and liver [see warnings and precautions (5.7)] - pediatric patients (less than 18 years). everolimus is contraindicated in patients with known hypersensitivity to everolimus, sirolimus, or to components of the drug product. risk summary based on animal studies and the mechanism of action [see clinical pharmacology (12.1)], everolimus can cause fetal harm when administered to a pregnant woman. there are limited case reports of everolimus use in pregnant women; however, these reports are insufficient to inform a drug associated risk of adverse developmental outcomes. reproductive studies in animals have demonstrated that everolimus was maternally toxic in rabbits and caused embryo-fetal toxicities in rats and rabbits, at exposures near or below those achieved in human transplant patients. advise pregnant women of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. data animal data everolimus crossed the placenta and was toxic to the conceptus. everolimus administered daily to pregnant rats by oral gavage at 0.1 mg/kg (approximately one tenth the exposure in humans administered the lowest starting dose of 0.75 mg twice daily), from before mating through organogenesis, resulted in increased preimplantation loss and embryonic resorptions. these effects occurred in the absence of maternal toxicities. everolimus administered daily by oral gavage to pregnant rabbits during organogenesis resulted in abortions, maternal toxicity and lethality, and increased fetal resorptions. at these doses, exposure to everolimus (auc) was approximately one-tenth, one-half, and one and one-half fold the exposures in humans administered the starting clinical dose, respectively. in a pre- and post-natal development study in rats, animals were dosed from implantation through lactation. at a dose of 0.1 mg/kg (0.6 mg/m2 ), there were no adverse effects on delivery and lactation or signs of maternal toxicity; however, there were reductions in body weight (up to 9% reduction) and in survival of offspring (~5%). there were no drug-related effects on the developmental parameters (morphological development, motor activity, learning, or fertility assessment) in the offspring. risk summary there is no data regarding the presence of everolimus in human milk, the effects on breastfed infants, or the effects on milk production. everolimus and/or its metabolites are readily transferred into milk of lactating rats at a concentration 3.5 times higher than in maternal rat serum. in pre-post-natal and juvenile studies in rats, exposure to everolimus during the postnatal period caused developmental toxicity [see use in specific populations (8.1), nonclinical toxicology (13.2)]. advise lactating women not to breastfeed because of the potential for serious adverse reactions in infants exposed to everolimus. contraception females should not be pregnant or become pregnant while receiving everolimus. advise females of reproductive potential that animal studies have been performed showing everolimus to be harmful to the mother and developing fetus [ see use in specific populations (8.1)] . females of reproductive potential are recommended to use highly effective contraception methods while receiving everolimus and up to 8 weeks after treatment has been stopped. infertility females amenorrhea occurred in female patients taking everolimus [ see adverse reactions (6.2)]. everolimus may cause pre-implantation loss in females based on animal data [see nonclinical toxicology (13.1)]. female fertility may be compromised by treatment with everolimus. males everolimus treatment may impair fertility in males based on human [see warnings and precautions (5.18), adverse reactions (6.2, 6.3)] and animal findings [see nonclinical toxicology (13.1)]. the safe and effective use of everolimus in kidney or liver transplant patients younger than 18 years of age has not been established. there is limited clinical experience on the use of everolimus in patients of age 65 years or older. there is no evidence to suggest that elderly patients will require a different dosage recommendation from younger adult patients [see clinical pharmacology (12.5)] . everolimus whole blood trough concentrations should be closely monitored in patients with impaired hepatic function. for patients with mild hepatic impairment (child-pugh class a), the dose should be reduced by approximately one-third of the normally recommended daily dose. for patients with moderate or severe hepatic impairment (child-pugh b or c), the initial daily dose should be reduced to approximately half of the normally recommended daily dose. further dose adjustment and/or dose titration should be made if a patient's whole blood trough concentration of everolimus, as measured by an lc/ms/ms assay, is not within the target trough concentration range of 3 to 8 ng/ml [see clinical pharmacology (12.6)]. no dose adjustment is needed in patients with renal impairment [see clinical pharmacology (12.6)].

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

par pharmaceutical, inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1) ] everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. tdm of everolimus and cyclosporine is recommended for all patients receiving these products. [see dosage and administration (2.2, 2.3) ] everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus is to be administered no earlier than 30 days post-transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5) and clinical studies (14.2) ]. therapeutic drug monitoring (tdm) of everolimus and tacrolimus is recommended for all patients receiving these products. [see dosage and administration (2.3, 2.5) ] the safety and efficacy of everolimus has no

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus oral solution is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. in patients at low-to moderate-immunologic risk , it is recommended that sirolimus oral solution be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration (2.2) ]. in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level >80%]), it is recommended that sirolimus oral solution be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration (2.3) , clinical studies (14.3) ]. cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawa

Kanada - engleski - Health Canada

abbvie corporation - cyclosporine - emulsion - 0.05% - cyclosporine 0.05% - anti-inflammatory agents, miscellaneous

Kanada - engleski - Health Canada

santen incorporated - cyclosporine - emulsion - 0.1% - cyclosporine 0.1% - anti-inflammatory agents, miscellaneous

Kanada - engleski - Health Canada

novartis pharmaceuticals canada inc - cyclosporine - solution - 50mg - cyclosporine 50mg - immunosuppressive agents

Kanada - engleski - Health Canada

novartis pharmaceuticals canada inc - cyclosporine - capsule - 100mg - cyclosporine 100mg - immunosuppressive agents

Kanada - engleski - Health Canada

novartis pharmaceuticals canada inc - cyclosporine - solution - 100mg - cyclosporine 100mg - immunosuppressive agents

Kanada - engleski - Health Canada

novartis pharmaceuticals canada inc - cyclosporine - capsule - 25mg - cyclosporine 25mg - immunosuppressive agents

Kanada - engleski - Health Canada

novartis pharmaceuticals canada inc - cyclosporine - capsule - 50mg - cyclosporine 50mg - immunosuppressive agents